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Characterized tissue with pathological grading and blood samples as well as other bioﬂuids
forms  the basis for all biobanks as a resource in modern life science. Biobanks are accessed to
measure biological components that can be used to monitor the status of health and disease
in  individual samples and population groups. The biomarker diagnostics area, predicting
drug  efﬁcacy, stratiﬁcation of patient groups, can beneﬁt from the continuous qualitative
developments,  where Proteomics can make a difference in lung cancer and COPD. This ineywords:
ung cancer
OPD
iobank
athology
turn  can provide key treasures to novel drugs for personalized medicine in the future.
©  2013 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). Open access under CC BY license..  Biobank  infrastructure  within  healthcare
he healthcare sector throughout the world is undergoing
ajor changes in order to meet the increasing demand of
atient  care. Biobanks are a major resource for scientists to
ccess  unique patient samples for medical research. Many
tudies  within clinical proteomics utilize stored samples con-
ained  in biobanks to measure speciﬁc end points. Biomarker
tudies  within the proteomics research ﬁeld have been a
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ttp://dx.doi.org/10.1016/j.euprot.2013.04.001major focus for many  research teams. This is illustrated by a
Google search where more  than 3.5 million hits come up using
Biomarkers  Proteomics as keywords. The success and output
of  these initiatives has been poor, and one important reason
for  the limited usability of Proteomics data is most probably
linked  to the quality of Biobank samples from patients.al Center, Department of Measurement Technology and Industrial
den. Tel.: +46 46 222 3402; fax: +46 46 222 4521.
Standardizations and quality control of samples being
processed for storage as well as retrieval of stored samples
are  important goals in order to support the development of
diagnostic  biomarkers [1]. Today we have not yet achieved
mics Association (EuPA). Open access under CC BY license.
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Fig. 1 – Biobank work ﬂow where the patient sample is processed and aliquoted in high density tubes systems and stored
in low temperature biobank freezer units with robotic handling and processing at −80 ◦C.consensus on how to collect, manage, and build biobank
archives in order to reach goals where these efforts are trans-
lated into value for the patient. This is currently a challenge
where lack of available high quality sample collections with
a wide range of disease cohorts has become a rate-limiting
step for drug development, medical research and novel diag-
nostics. In order to provide best support to patients, it is clear
that improvements and developments within healthcare will
be closely linked to the introduction of new technology plat-
forms. Novel technologies as improved tools and concepts
will be associated with the ability to preserve the sample
integrity of bio-samples that are stored for periods that will
reach one or several decades as illustrated in Fig. 1. In addi-
tion, the availability of samples that are available as a global
resource within a documented Biobank repository will be
key, in order to perform comparative studies where we make
use of clinical data that are associated to patients, such as
metadata of measurements and clinical phenotyping. These
progressive developments were recently presented in several
international initiatives in order to disseminate best practice
examples for biobanking [2,3].
Today in Europe, the Biobanking and Biomolecular
Resources Research Infrastructure (BBMRI) currently has a
54-member consortium by means of 225 associate orga-
nizations from over 30 countries. International utilization
of bio-samples across country borders serves as integratedresources, using bio-repository patient material to develop
healthcare needs of tomorrow. The outstanding demand in
most countries in hospitals is putting a high demand on mod-
ern healthcare, where the fast progress in clinical research
has created a large demand for blood, tissue and other clin-
ical samples used in genomics and proteomics studies [4].
Today we  invest hundreds of millions of dollars internation-
ally on the collection, storage and distribution of samples.
Biorepository archives in Europe, as well as other continents,
rest on best practice experience, as well as quality assurance
based tests and assays, without any agreed and approved
guidelines. We  have been able to resolve that by introducing
basic standardization requirements and protocols, as an ini-
tial quality assurance guideline [5,6]. Recently, a large-scale
384-format biobank sample tube system was introduced that
will allow us to make global Proteomics multi-center studies
[7]. Since the patient blood sample volumes are low, 50–70 L,
multiple aliquots are being collected from each blood frac-
tions, e.g., plasma, leucocyte fraction, serum and whole blood
[8].
In clinical practice today we  have more  than 100 protein tar-
gets that are utilized for clinical assay screening, from where a
combination of biomarker read-outs will be used as the basis
for medical diagnosis of patients [9].
In order to regulate protein expression data output and
build on clinical disease value for patients, there are biobank
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aws  attached, to regulate these activities in each respective
ountry. The biobank documents are very extensive and
egulates the way that clinical samples and the resulting
utcomes can be use and the utility of patient samples that
as been collected in large well-organized biobank archives.
ately, the speciﬁc requirements that are needed for Biobank
evelopments with respect to patient sampling workﬂow,
as been taken into consideration and dedicated protocols to
ptimize the stability of proteins has been taken into practice
http://lifescience.skane.org/content/new-development-
ffers-unique-and-increased-opportunity).
Usually, informed consents from patients are the basis for
ny bio-sample use in clinical science, where the patient has
een informed on the objectives and future healthcare use
or fellow patients. Consequently, documentation regulates
he availability of the sample usage. In most cases, this is
eclared in a clinical study protocol, or other types of study
ocumentation. The practical parts are handled in a manner
hat promotes integrity and that is aligned with legal consid-
rations.
International guidelines that are regulated by biobank laws
nd approved by ethical boards are already today common
ractice that the research community as well as the authori-
ies like FDA and EMEA live by. What is in progress in order to
apitalize on the Biobank investments are the documentation
nd quality aspects that will drive the usability of all these
tored samples that is a resource treasure well stored.
ig. 2 – Transbronchial biopsy specimen. (A) Normal epithelium 
denocarcinoma exibits a EGFR-negative status (arrow). (B) Sange
2/11. Note the activating mutation at c2236 2250del15 (cosmic ID s 1 ( 2 0 1 3 ) 3–7 5
2.  Lung  cancer  and  personalized  drug
treatment
2.1.  Molecular  phenotyping:  the  association  of  drugs
with tumor  type
A paradigm shift was witnessed in the management of lung
cancer in the past decade due to two factors. Pathological
diversity of lung cancer was translated to histology-associated
chemotherapeutic protocols recognizing the basic entities as
squamous cell cancer, adenocarcinoma and small cell lung
cancer (Fig. 2A). Parallel to these developments, a molecular
sub-classiﬁcation of lung cancer was started to be established
which is now detailed enough in adenocarcinoma but starting
to be useful in other histological variants as well. Molecu-
lar classiﬁcation of lung adenocarcinoma revealed that the
major driver mutation is K-RAS [10] followed by EGFR, B-RAF
and ALK-fusions [11–13] where several efﬁcient therapeutics
are already available (Fig. 2B). As a consequence lung can-
cer is now an example of personalized medicine where target
therapy improved progression-free as well as overall survival
of lung cancer patients, now frequently allowing second or
third line of treatments. However, the basis of this develop-
ment was the close collaboration of pathology, pulmonology
and molecular biology. Unfortunately, lung cancer is the
only major human cancer where cytological diagnosis is still
exhibits strong EGFR protein expression while
r sequencing of EGFR exon 19 in lung adenocarcinoma TPL
:6225).
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signiﬁcantly frequent and where the primary tumor is
inoperable in the majority of cases. Accordingly molecular
diagnostics and biobanking of lung cancer provide the major
challenges due to insufﬁcient amount of primary tumor tis-
sue. Furthermore, small biopsy samples or cytological smears
are not representing the pathological and molecular hetero-
geneity of the tumor. These issues can be overcome by heavily
relaying on metastatic samples or body ﬂuids such as pleu-
ral effusions or blood serum. While lung cancer biobanks are
already serving the successful therapy of patients, the rapid
development of molecular pathology and target therapy of
lung cancer is also due to these resources further justifying
the concept.
The ﬁrst personalized medicine for lung cancer patients
was the tyrosine kinase inhibitor Geﬁtinib (IRESSA) [14],
introduced in Japan, where follow-up protein biomarker stud-
ies were initiated and reported on [15]. Protein markers as
targets for predicating optimal patient efﬁcacy and safety has
been the center of research for a number of years where
the drug development goes from traditional chemotherapy,
radiation treatment and to the new generation of targeted
treatments. The present status and best practice of clini-
cal proteomic analysis for early detection and determination
of therapeutic strategy in lung cancer was outlined and
introduced, as an example of protein expression strategies
[16–18]. A recent paper by Kato et al., illustrates the status of
proteomics studies and initiatives over more  than a decade
with a focus on the clinicians view and worked out experi-
ences of proteomic studies in the Light of Lung Cancer [12].
3.  COPD  grading  and  disease
pathophysiology
Chronic obstructive pulmonary disease (COPD), a heteroge-
neous and progressive pulmonary disorder characterized by
airway obstruction, systemic manifestations and increasing
frequency and severity of exacerbations, affects more  than
0.2 billion people worldwide and is expected to rise to the
third leading cause of death by 2030 [19]. Although COPD is
mainly caused by smoke inhalation, it has become obvious
that other noxious agents such as burning biomass fuels in
poorly ventilated homes can also play a role in its develop-
ment [20]. Nevertheless, the mechanistic concepts that have
been implicated in the pathogenesis of the disease include:
(i) chronic airway inﬂammation in response to inhaled nox-
ious particles, (ii) host factors including genetic susceptibility,
epigenetic changes, and oxidative stress, (iii) an imbalance
between proteases versus antiproteases and oxidants versus
antioxidants leading to a net increase in proteolytic activity,
oxidative stress and apoptosis of structural cells. These mech-
anisms, however, do not operate separately; in fact, they are
interlinked, participating concurrently in COPD progression
[21]. Recent protein expression studies have provided evidence
of proteins that have been differentially regulated, with clear
implications to a disease link [21].Similarly to lung cancer, a major challenge in COPD drug
development is to identify molecular and imaging-based
biomarkers that could be used to deﬁne surrogate outcomes in
clinical trials and, moreover, to identify those patients who are c s 1 ( 2 0 1 3 ) 3–7
likely to beneﬁt from emerging drugs [22]. Biomarker studies
in complex disorders like COPD, however, have to overcome
the challenge of disease heterogeneity. In addition, although
there is an obvious need for higher case numbers in COPD
phenotyping studies to overcome this obstacle, this need is
further challenged by the small number of adequately pre-
served pulmonary tissue samples available. Thus, because
only high-quality biological samples can provide the data
needed for biomarker research, biobanking has also a key role
in developing more  effective anti-COPD strategies. In the Euro-
pean Union funded EvA (emphysema versus airway disease)
study, we are investigating more  than 800 biobanked sam-
ples from both cases and controls [23]. Our consortium aims
to identify novel markers for COPD and its main phenotypes
(i.e., emphysema and airway disease), by analyzing bronchial
and alveolar gene expression patterns in COPD patients and
matched controls. To this aim, patients go through pulmonary
function analysis and chest CT (used to deﬁne the pheno-
types based on lung density and airway wall thickness). Then
bronchial brush and lavage samples taken by bronchoscopy
along with blood samples are being subjected to genome-wide
expression and association analysis and biomarkers linked to
the phenotypes are identiﬁed.
4.  Conclusions
Looking into the pipeline of forthcoming drug products,
personalized medicines, as well as antibody-based bio-
pharmaceuticals are anticipated to grow signiﬁcantly. The
most important part of any drug development is the access
to high quality clinical samples. Both speciﬁc tissue com-
partments, characterized by pathology, blood samples and
other bioﬂuid samples and specimens are the basis for all
biobanks as a resource. By continuous improved standardiza-
tion and qualitative developments will provide key treasures
to novel drugs in the future. The biomarker diagnostics area,
predicting drug efﬁcacy, stratiﬁcation of patient groups, and
aiding in safety assessment, will also grow as a result of these
developments. All of these changes for the better in modern
healthcare will be driven from successful implementation of
translational science, progressing both in the pharmaceuti-
cal and biotechnology industry, as well as within academic
research.
Recently, a report came out that proposes Proteomics
strategies in order to improve international research biobank
sample usage of clinical specimens [24].
One should also bear in mind that the value of the sam-
ples is dependent upon developing workﬂows that enable their
use. The Human Chromosome Initiative as well as other global
research activities is looking for best practice and applicability
that can bring value and bridge the data sets of information
held with each clinical sample. One of the major objectives
is to build data collections that can be used to create future
paradigms of healthcare and treatment modalities [25,26].Acknowledgements
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